Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ABBV lowers adjusted earnings guidance for 2024 from $10.71-$10.91 per share to $10.67-$10.87 to account for acquisition costs.

AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs

AbbVie (ABBV) closed the most recent trading day at $195.45, moving -0.7% from the previous trading session.

AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights

AbbVie on Thursday lowered its forecast for 2024 adjusted profit, citing $82 million in milestones, and research and development expenses related to acquisitions.

AbbVie cuts 2024 profit forecast on R&D expenses

AbbVie's acquisition of Cerevel Therapeutics enhances its neuroscience pipeline with promising candidates Emraclidine and Tavapadon, expected to significantly boost revenues post-approval. Emraclidine and Tavapadon show strong clinical trial results, positioning them as potential best-in-class treatments for Schizophrenia and Parkinson's Disease, respectively. AbbVie demonstrates financial strength with rising revenues from Skyrizi and Rinvoq, supporting a bullish long-term investment thesis despite Humira's decline.

AbbVie's Emraclidine: M4 Agonist Might Become Best-In-Class In Schizophrenia

Eli Lilly

Merck

The pharmaceutical industry plays a crucial role in most of our everyday lives.

3 Top Pharma Stocks to Buy in October 2024

AbbVie presents a strong long-term investment opportunity, driven by its strategic focus on neuroscience and IBD treatments, despite challenges from Humira's decline. Tavapadon and other neuroscience drugs offer substantial growth potential, addressing unmet medical needs in Parkinson's and other neurological conditions. Skyrizi and Rinvoq are rapidly growing, offsetting Humira's revenue decline, and positioning AbbVie to capture significant market share in the expanding IBD market.

AbbVie: A Strong Investment Opportunity In Neurological And Oncology Breakthroughs

Bank of America

Bank of New York Mellon

Blackrock Inc

Caterpillar

Citizens Financial Group

Cigna

Deere & Company

Discover

Fastenal

Fifth Third Bancorp

Goldman Sachs

Interpublic Group of Companies

JPMorgan Chase & Co

KeyCorp

Lamb Weston Hlds

Morgan Stanley

Omnicom Group

Otis Worldwide

PNC Financial Services

Regions Financial

Ralph Lauren

Charles Schwab

Simon Property Group

Steel Dynamics

Entering October is the strongest period of the year for three-month returns, and shorter-term returns are also some of the best. Here we take a look at 30 dividend stocks in the S&P 500 that have been the best Q4 performers over the last ten years. 2024 has been a strong year already for high-yielding stocks, and now they have Q4 seasonality as another tailwind.

Dividend Stocks With Strong Q4 Seasonality

AbbVie has transitioned beyond Humira's exclusivity loss, with strong growth from Skyrizi and Rinvoq, targeting $27 billion in sales by 2027. The stock has surged to $200, now trading at 16x 2025 EPS targets, making it less of a bargain. AbbVie's dividend yield is 3.1%, with a potential hike to 3.3% in October, but debt remains high at over $60 billion.

AbbVie: $200 Peak (Rating Downgrade)

AbbVie's high-growth investment thesis is undeniable indeed, despite Humira's painful patent expiry and the erosion observed in its sales thus far. Our optimism arises from Skyrizi's/Rinvoq's promising double-digit growth, excellent ex-Humira portfolio sales growth, and the management's raised FY2024/FY2027 guidance. ABBV's balance sheet health remains reasonable as well, attributed to the projected expansion in its Free Cash Flow generation over the next few years.

AbbVie's Skyrizi And Rinvoq Deserve The Premium Growth Valuation

JUVÉDERM® VOLUMA® XC is the One and Only Hyaluronic Acid Dermal Filler Indicated to Treat Cheeks, Chin, and Now Moderate to Severe Temple Hollowing1,2 Only Allergan Aesthetics, the Makers of BOTOX® Cosmetic (onabotulinumtoxinA), has FDA-Approved Injectables to Treat More Than 90% of the Face2-8 IRVINE, Calif. , Oct. 2, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the national availability of JUVÉDERM® VOLUMA® XC for temple hollowing.

Available Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing

American Express

Costco

Microsoft

These five stocks are known for their generous dividend programs and robust business models.

5 Best Dividend Growth Stocks to Buy in October

Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.

Should You Buy AbbVie Stock After Recent Parkinson's Study Success?

The European Medicines Agency said on Tuesday that it has withdrawn the marketing authorisation for Abbvie's hepatitis C drug Exviera at the request of the company.

EU withdraws marketing authorisation for Abbvie's hepatitis C drug

NORTH CHICAGO, Ill. , Oct. 1, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2024 financial results on Wednesday, October 30, 2024, before the market opens.

AbbVie to Host Third-Quarter 2024 Earnings Conference Call

AbbVie (ABBV) stock price has done well this year as it surged to a record high of $200. It has jumped by more than 32% this year, outperforming the S&P 500 and Nasdaq 100 indices.

AbbVie stock analysis: Rinvoq and Skyrizi are big catalysts

ABBV submits a BLA for Teliso-V to the FDA for treating previously treated non-small cell lung cancer patients with c-Met overexpression.

AbbVie Seeks Approval for Lung Cancer Candidate Teliso-V

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It?

W.W. Grainger

Johnson & Johnson

Coca-Cola

Lowe's

Altria

Realty Income Corp

PepsiCo

Pfizer

Philip Morris

S&P Global

AT&T

Target

Visa

Dividend sustainability trumps high yields when selecting stocks for passive income. The featured companies span diverse sectors including healthcare, consumer goods, retail, finance, and real estate.

15 Best Dividend Stocks for Lifelong Passive Income

Data from a late-stage study shows that AbbVie's tavapadon reduced the burden of Parkinson's disease. The drug previously demonstrated efficacy as adjunctive therapy.

ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal

- Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression. - Biologics License Application (BLA) submission for accelerated approval is supported by data from the Phase 2 LUMINOSITY trial (M14-239).

AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer

Novo Nordisk is a great business, but its dividend profile isn't nearly as impressive. That contrasts with AbbVie's dividend record, which has proven excellent over time.

Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead

AbbVie said on Thursday its drug met the main goal in a late-stage trial in patients with early Parkinson's disease.

AbbVie's Parkinson's Disease drug meets main goal in late-stage trial

Tavapadon met the primary endpoint in the pivotal Phase 3, TEMPO-1 fixed-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III combined score at week 26 Trial also met key secondary endpoint, demonstrating statistically significant improvement from baseline in the MDS-UPDRS Part II score Results from the Phase 3 TEMPO-2 trial, studying tavapadon as a flexible-dose monotherapy, are expected by the end of 2024 NORTH CHICAGO, Ill. , Sept. 26, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease.

AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease

Bristol-Myers

Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – AbbVie stock . BMY stock trades at a much lower multiple of 2.2x revenues, versus 6.2x for ABBV.

Bristol Myers Squibb Vs. AbbVie Stock

News for AbbVie Stock (ABBV)